Aspire Biopharma Faces Delisting Notice

Ticker: ASBPW · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1847345

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Aspire Biopharma (ASBP) got a delisting warning.

AI Summary

Aspire Biopharma Holdings, Inc. filed an 8-K on April 18, 2025, to report its notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp., with a name change date of February 22, 2021.

Why It Matters

This filing indicates potential issues with Aspire Biopharma's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.

Key Players & Entities

FAQ

What specific listing rule or standard has Aspire Biopharma Holdings, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Aspire Biopharma Holdings, Inc. has failed to satisfy, only that a notice has been issued.

What is the ticker symbol for Aspire Biopharma Holdings, Inc.?

The ticker symbol is not explicitly stated in this excerpt, but the former names suggest it might be related to an acquisition company.

When was the company formerly known as PowerUp Acquisition Corp.?

The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp. with a date of name change on February 22, 2021.

What is the business address of Aspire Biopharma Holdings, Inc.?

The business address is 194 Candelaro Drive, #233, Humacao, PR 00791.

What is the Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing